Xenetic Biosciences partner cleared for Israeli CAR T-cell combination study
Xenetic Biosciences (NASDAQ:XBIO) announced today that its collaboration partner, PeriNess, has received formal approval from the Israeli Ministry of Health and the relevant Institutional Review Board to initiate an exploratory clinical study.





-640x360.webp&w=3840&q=75)




